International agreement for Biolight

International agreement for Biolight Biolight has reached an agreement with the British dental company TryCare Ltd., granting TryCare exclusive rights to sell Biolight Dental Care in Great Britain. Periodontitis (loosening of the teeth) is a very common disease leading to considerable treatment costs for the public health service every year. Biolight's effective and clinically verified method may add a new dimension to public dental care, according to TryCare, which is one of the new market-oriented distribution companies within dental care products in the British market. This agreement is the first one to be concluded in a process where Biolight is selecting international distributors for Biolight Dental Care (dental care products). "Biolight Dental Care will add a completely new dimension to public dental care in Great Britain," says Phil Mathers, CEO of TryCare Ltd. Periodontitis is a very common disease. In Europe, about 40 per cent of the population over 40 years of age have some kind of gum inflammation. Without treatment, swollen and bleeding gum may develop into loss of connective tissue and, eventually, loss of teeth. Through the Biolight method, which is painless and external, treatment of an inflammatory condition may be completed within a period of ten days with one treatment per day. The sales potential is estimated at about SEK five billion (EUR 526 million) per year, in Europe alone. "The compensation for treating patients with periodontitis and similar dental diseases is not sufficient in Great Britain, neither for covering the treatment time, nor for the extensive surgical actions needed, and far too often this leads to patients developing chronic infections that must be treated in hospital. This leads to considerable costs for the NHS and to patients having to endure lengthy, painful treatment," says Phil Mathers, CEO of TryCare. "Biolight Dental Care provides dentists and dental hygienists with the possibility to offer non-surgical treatment as an alternative solution to these problems. Even if the patient would have to pay himself, the cost, estimated at about SEK 4,500 (EUR 475), is comparatively low and we think that many dentists will offer their patients this treatment as a perfect alternative to surgery," Phil Mathers concludes. "We have put more than 20 years experience of treatment with monochromatic light into our technology," comments Christer Wallin, president of Biolight International AB. "We are very pleased to see that TryCare will now distribute our products in Great Britain. TryCare is an excellent partner with their close relationship to dentists and the market. In addition to their great knowledge, extensive experience and many years of successful operation, they have also proved their great ability to introduce and sell new concepts." For further information, please contact: Christer Wallin, president, Biolight International AB, tel. +46-(0)8-622 52 70 Phil Mathers, CEO, TryCare, +44-1274-88 10 44 Facts about Biolight: Biolight International AB (publ) is a medical technology company that has developed a unique product for the treatment of damaged cells. The product, which is patent protected, is based on a method where light of a certain wavelength (monochromatic light) and pulse frequency is applied during specific periods of time. This light provides energy to the cell, increasing its activity and initiating healing. Without sufficient energy a cell is not strong enough to contribute to healing. The method speeds the healing processes and supplements traditional treatment. It contributes to improved life quality and reduces treatment costs. The treatment is non-pharmaceutical (not a drug) and external. It is easy to administer, painless and does not involve any side effects. Today, Biolight is successfully used in wound care, dental care and rehabilitation. Clinical studies, involving the same stringent design as in drug studies, have shown that the Biolight method significantly reduces time to healing, for gum inflammation as well as for chronic wounds. A phase III study regarding gingivitis shows that inflammations in patients treated with Biolight® were reduced by 87 per cent more than in patients receiving traditional treatment. Facts about TryCare: Turnover: MSEK 40 (EUR 4.2 million) Number of employees: 12 Established: In 1997 Business concept: Education, seminars, active sales activities Product focus: Innovative "high-tech" products Operates in the following market: Great Britain Other products sold by TryCare: Dental consumer products, Getinge, Rocky Mountain, Dürr, Nordiska Dental, Mölnlycke, Direkta Dental, Generic Pentron Phil Mathers: Former CEO and a major owner of Procare Dental Group (MSEK 360 (EUR 38 million). Mr Mathers has 27 years experience in marketing and sales of dental products in the British market. Biolight International AB is a medical technology company, offering its customers, including patients, nursing staffs and authorities, various products and services based on the company's patented method for the use of pulsating, monochromatic light. The company aims to improve the quality of life for the patients and reduce the time to healing and treatment costs significantly. Through systematically executed clinical trials, Biolight is gradually extending the scientific basis needed to guarantee the method a solid position in the health care field. During the past few years, Biolight has focused on a small number of indication areas grouped around wound healing. For further information, please visit Biolight's homepage www.biolight.se or contact Christer Wallin, President of Biolight International AB, on +46-(0)8-622 52 70. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2001/10/15/20011015BIT00720/bit0001.doc http://www.waymaker.net/bitonline/2001/10/15/20011015BIT00720/bit0001.pdf